Eco Petroleum Solutions, Inc. Announces Exclusive Distribution Agreement with IMMB BG
June 22, 2017 at 06:45 pm
Share
Eco Petroleum Solutions, Inc. announced that IMMB BG has issued an exclusive Distribution Agreement for the territory of the Ukraine to LLC Project Development and Implementation Centre Omega. The term of the agreement is for an initial ten-year period with an option to renew the agreement for an additional ten years. The Agreement establishes a price of EUR 3,300 per one 8-week cycle of injections or 16 vials. The treatment protocol requires two 8-week cycles of injections administered twice a week with a one-week break between cycles. The ITV-1 treatment will be administered with a combination of different variations of Protease Inhibitors used in the treatment of HIV/AIDS. The Agreement established a minimum order as 50 doses of the treatment, or 800 vials. The first order placed is for 10,000 units which will undergo manufacturing validation and then delivered to Omega for sale in the Ukraine as soon as the manufacturing permit is issued, which is expected within the next 180 days. This initial validation order is valued at EUR 2,062,500 (USD 2,116,125). The validation documentation will be completed in batches of 3,300 and necessary documentation to complete the registration process is anticipated to be completed and delivered to the Bulgarian Drug Administration (BDA) by the end of September. The company expects additional orders to be placed in similar quantities on a monthly basis after the issuance of the permit.
Enzolytics, Inc. is a drug development company. The Company is engaged in the commercialization of its proteins and monoclonal antibodies for the treatment of debilitating infectious diseases. Its patented and clinically tested compound, ITV-1 (Immune Therapeutic Vaccine-1), is a suspension of Inactivated Pepsin Fraction (IPF) for the treatment of human immunodeficiency virus/ acquired immunodeficiency syndrome (HIV/AIDS). It has a technology for producing fully human monoclonal antibodies (mAbs) against infectious diseases which is being employed to produce monoclonal antibody therapeutics for treating the Coronavirus (SARS-CoV-2), HIV-1 and the Feline Leukemia virus. The Company also plans to produce mAbs targeting many other viruses, including HIV-2, Influenza A and B, H1N1 influenza, Respiratory syncytial virus (RSV), Small-Pox, Ebola Virus, Tetanus, Diphtheria, HTLV-1/2, Rabies, Herpes zoster, Varicella zoster, Anthrax, Mason-Pfizer monkey virus (MPMV) and Visna virus (VISNA).